June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Choroidal Thickness of Branch Retinal Vein Occlusion
Author Affiliations & Notes
  • Kenji Sogawa
    Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
  • Taiji Nagaoka
    Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
  • Tomofumi Tani
    Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
  • Ichiro Tanano
    Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
  • Akitoshi Yoshida
    Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
  • Footnotes
    Commercial Relationships Kenji Sogawa, None; Taiji Nagaoka, None; Tomofumi Tani, None; Ichiro Tanano, None; Akitoshi Yoshida, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 268. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kenji Sogawa, Taiji Nagaoka, Tomofumi Tani, Ichiro Tanano, Akitoshi Yoshida; Choroidal Thickness of Branch Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2013;54(15):268.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate the choroidal thickness in patients with branch retinal vein occlusion (BRVO).

Methods: We examined the bilateral subfoveal choroidal thickness using enhanced depth imaging optical coherence tomography (EDI-OCT) in 50 eyes of 50 patients (mean age 64.3±10.3 years, 23 females and 27 males) with BRVO. Macular edema was evaluated by using spectral domain OCT (RTVue®). Patients were excluded if they had other ocular disease or had no macular edema (<300μm) or the duration of the BRVO was long (>3 months). Thirty-two of 50 eyes patients were treated with intravitreal bevacizumab (IVB) (1.25mg/0.05ml) and measured the subfoveal choroidal thicknesses before and after the treatment.

Results: The mean central macular thickness of BRVO eyes was 514.8±116.3μm. The mean subfoveal choroidal thickness was 263.5±79.1μm and 241.2±72.6μm in BRVO eyes and fellow eyes, respectively. There was no significant difference in the choroidal thickness between BRVO eyes and fellow eyes (p=0.078). There was no correlation between central macular thickness and subfoveal choroidal thickness. The mean subfoveal choroidal thickness after IVB was 239.7±69.3μm, which was not significant change compared with the mean subfoveal choroidal thickness before IVB.

Conclusions: There was no significant difference between the subfoveal choroidal thickness of BRVO eyes and fellow eyes. Because the subfoveal choroidal thickness of BRVO did not change significantly after IVB, it is speculated that blockade of vascular endothelial growth factor may have little influences on subfoveal choroidal thickness in BRVO eyes.

Keywords: 452 choroid  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×